Kaposi's varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab.

BACKGROUND: Immune-directed therapies have become front-line therapy for melanoma and are transforming the management of advanced disease. In refractory cases, multi-modal immunoncology (IO) approaches are being utilized, including combining immune checkpoint blockade (ICB) with oncolytic herpes viruses. Talimogene laherparepvec (T-VEC) is the first genetically modified oncolytic viral therapy (OVT) approved for the treatment of recurrent and unresectable melanoma. The use of IO in patients with concomitant malignancies and/or compromised immune systems is limited due to systematic exclusion from clinical trials. For example, a single case report of a solid organ transplant patient successfully treated with T-VEC for metastatic melanoma has been reported. Furthermore, the use of ICB in T-cell malignancies is limited and paradoxical worsening has been described. To our knowledge, this is the first report of dual ICB/T-VEC being administered to a patient with concurrent primary cutaneous anaplastic large cell lymphoma (pcALCL) and melanoma. CASE PRESENTATION: Here we present the case of a patient with concomitant primary cutaneous ALCL and metastatic melanoma, progressing on anti-programmed death (PD)-1 therapy, who developed Kaposi's varicelliform eruption after receiving the first dose of Talimogene laherparepvec. CONCLUSION: This case highlights the complexities of care of patients with coexistent cancers, demonstrates rapid progression of primary cutaneous ALCL on nivolumab and introduces a novel adverse effect of Talimogene laherparepvec.

Delayed hypersensitivity to hydroxychloroquine manifested by two different types of cutaneous eruptions in the same patient / Hipersensibilidad retardada al hidroxicloroquina manifestada por dos diferentes tipos de erupción cutánea en el mismo paciente

Hydroxychloroquine (HXQ) sulphate is a synthetic antimalarial drug that is widely used in rheumatology due to its immunosuppressive properties. Delayed-type sensitization to this drug is rare. A 47-year-old woman diagnosed with HLA B27 ankylosing spondylitis was treated with HXQ for 22 days and had to discontinue the drug due to gastric intolerance. Five days later the patient developed erythema multiforme (EM) with an extensive and unusual distribution. Patch tests with 10 % HXQ in DMSO were positive at 48 hours. Eight days later a generalized pruriginous erythematous papular exanthema developed, and a skin biopsy was obtained. The first reaction was EM. Patch-testing elicited systemic eczematous contact dermatitis. We report two different clinical patterns of delayed hypersensitivity in the same patient and with the same drug

El sulfato de hidroxicloroquina (HXQ), es un antipalúdico de síntesis ampliamente usado en reumatología por sus propiedades inmunosupresoras. Las reacciones de hipersensibilidad retardada a este fármaco son excepcionales. Una mujer de 47 años, diagnosticada de espondilitis anquilosante, fue tratada con HXQ durante 22 días, teniendo que interrumpir el tratamiento por intolerancia gástrica. Cinco días después desarrolló un eritema multiforme (EEM) con una distribución amplia y atípica. Se realizaron pruebas de parche con HXQ al 10% en DMSO, que fueron positivas a las 48 hs. 8 días después, presentó un exantema papular eritematoso muy pruriginoso, realizándose biopsia cutánea en ese momento. La primera reacción fue un EEM. Las pruebas de parche desencadenaron una dermatitis de contacto sistémica. Describimos dos formas diferentes de hipersensibilidad retardada en el mismo paciente y con el mismo medicamento

Kaposi varicelliform eruption associated with 0.1% tacrolimus ointment treatment in atopic blepharitis.

OBJECTIVE: To report the association of Kaposi varicelliform eruption (KVE) with 0.1% tacrolimus ointment treatment of atopic blepharitis in a patient with atopic dermatitis (AD). METHOD: We encountered KVE in a 20-year-old male patient with atopic blepharitis and AD who developed generalized herpetic lesions on his face 28 days after commencement of treatment. RESULT: The lesions resolved quickly with intravenous acyclovir treatment. CONCLUSION: Ophthalmologists should be well aware of KVE as a complication of immunosuppressive treatment in patients with atopic blepharitis.